Pacira BioSciences, Parsippany, NJ, and Serrette Brown Research and Consulting, Danbury, CT.
Health Economics and Outcomes Research, Optum, Eden Prairie, MN.
J Manag Care Spec Pharm. 2021 May;27(5):586-595. doi: 10.18553/jmcp.2021.20343. Epub 2021 Feb 12.
Orthopedic surgery can be performed in hospital outpatient departments (HOPDs) and ambulatory surgical centers (ASCs), as well as in traditional inpatient venues. Patients who undergo orthopedic surgery may be prescribed opioids for the management of postsurgical pain. However, the association between surgery venue, postsurgical opioid use, and health care costs remains unclear. To compare postsurgical opioid use and health care costs associated with 6 different orthopedic surgical procedures performed at inpatient, ASC, and HOPD venues. Using the Optum Research Database, this retrospective study analyzed commercial health care claims from adult patients in the United States undergoing specific orthopedic procedures (total knee arthroplasty, partial knee arthroplasty, total hip arthroplasty, total shoulder arthroplasty, rotator cuff repair, and lumbar spinal fusion) between April 1, 2012, and December 31, 2017. The date of the first procedure in that period was the index date; continuous insurance coverage for 12 months before the index date (baseline period) to 6 months following the index date (postsurgical period, which includes the index date) was required. Opioid use and all-cause costs were measured in the postsurgical period. Baseline patient characteristics included demographics, Quan-Charlson Comorbidity Index, and opioid use. Multivariable analysis identified factors influencing postsurgical costs and persistent opioid use (defined as ≥ 1 opioid fill within 3 days after surgery [or discharge for inpatient stay] and ≥1 additional opioid fill during the postsurgical period at least 90 days after the index date). The sample included 126,172 patients (mean age, 58 years; 49% female). Overall, most procedures were performed at inpatient venues (68%), followed by HOPDs (18%) and ASCs (14%); the percentage of procedures performed at ASCs increased from 12% to 17% from 2012 to 2017. Patients whose procedures were performed at ASCs reported the lowest adjusted percentage of persistent opioid use following the procedure (18%) compared with those with procedures performed at HOPDs (24%) or inpatient venues (26%). Adjusted 30-day costs were 14% and 27% lower for patients with procedures in HOPDs and ASCs, respectively, compared with inpatient venues ( < 0.001 for both), and adjusted costs over the first 90 days were similar. All-cause costs on the day of surgery through 30 days after surgery for these 6 orthopedic procedures were significantly lower in HOPDs and ASCs compared with inpatient venues, even after adjustment for cohort, surgery year, demographic characteristics, baseline Quan-Charlson Comorbidity Index, and any opioid use within 90 days before the procedure. Additionally, patients undergoing orthopedic surgery at ASCs had the lowest adjusted percentage of persistent opioid use compared with those undergoing surgery at HOPDs or inpatient venues. Migration of certain orthopedic procedures from inpatient venues to HOPDs or ASCs may reduce health care costs and decrease the potential for persistent opioid use. This study and editorial support for the preparation of this manuscript was funded by Pacira BioSciences, which contracted with Optum to conduct the study. Cisternas, Korrer, and Wilson are employees of Optum. Waterman was employed with Pacira BioSciences at the time of the study. Portions of this work were presented at AMCP Nexus 2019; October 29-November 1, 2019; National Harbor, MD.
骨科手术可以在医院门诊部门(HOPD)和门诊手术中心(ASC)以及传统住院场所进行。接受骨科手术的患者可能会开处方使用阿片类药物来治疗术后疼痛。然而,手术场所、术后阿片类药物使用和医疗保健费用之间的关联尚不清楚。
比较在住院、ASC 和 HOPD 场所进行的 6 种不同骨科手术的术后阿片类药物使用和医疗保健费用。
本回顾性研究使用 Optum Research Database,分析了美国成年患者在 2012 年 4 月 1 日至 2017 年 12 月 31 日期间接受特定骨科手术(全膝关节置换术、部分膝关节置换术、全髋关节置换术、全肩关节置换术、肩袖修复术和腰椎融合术)的商业医疗保健索赔数据。该期间的第一次手术日期为索引日期;需要在索引日期前 12 个月(基线期)持续保险覆盖,并在索引日期后 6 个月(术后期,包括索引日期)进行保险覆盖。术后期间测量阿片类药物使用和全因费用。基线患者特征包括人口统计学、Quan-Charlson 合并症指数和阿片类药物使用情况。多变量分析确定了影响术后成本和持续阿片类药物使用的因素(定义为手术后 3 天内至少有 1 次阿片类药物填充[或因住院而出院],并且在索引日期后至少 90 天的术后期间至少有 1 次额外的阿片类药物填充)。
样本包括 126172 名患者(平均年龄 58 岁;49%为女性)。总体而言,大多数手术是在住院场所进行的(68%),其次是 HOPD(18%)和 ASC(14%);2012 年至 2017 年,ASC 进行的手术比例从 12%增加到 17%。与 HOPD(24%)或住院场所(26%)相比,在 ASC 进行手术的患者报告术后持续阿片类药物使用的调整后百分比最低(18%)。与住院场所相比,HOPD 和 ASC 进行手术的患者在术后 30 天的调整后 30 天成本分别降低了 14%和 27%(均<0.001),并且前 90 天的调整后成本相似。与住院场所相比,在 HOPD 和 ASC 进行这 6 种骨科手术的患者在手术当天至术后 30 天的全因费用显著降低,即使在调整了队列、手术年份、人口统计学特征、基线 Quan-Charlson 合并症指数以及手术前 90 天内任何阿片类药物使用情况后也是如此。此外,与在 HOPD 或住院场所接受手术的患者相比,在 ASC 接受骨科手术的患者调整后持续阿片类药物使用的百分比最低。某些骨科手术从住院场所转移到 HOPD 或 ASC 可能会降低医疗保健成本并减少持续阿片类药物使用的可能性。
这项研究和本手稿的编辑支持由 Pacira BioSciences 资助,该公司与 Optum 签订合同进行研究。Cisternas、Korrer 和 Wilson 是 Optum 的员工。Waterman 在研究期间受雇于 Pacira BioSciences。这项工作的一部分在 2019 年 AMCP Nexus 上进行了介绍;2019 年 10 月 29 日至 11 月 1 日;马里兰州国家港。